Category: Treatments

Peer-Reviewed Publications about COVID-19 (Coronavirus) by Yale Authors

Posted on | Posted on John Murphy | Leave a Comment on Peer-Reviewed Publications about COVID-19 (Coronavirus) by Yale Authors

Sharing knowledge about COVID-19 (coronavirus) is vital to our efforts as we fight the pandemic. Yale researchers are publishing their discoveries about COVID-19 (coronavirus) in peer-reviewed publications. Check back frequently to access the latest findings. Peer-Reviewed COVID-19 Publications from Yale A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?Tuan […]

Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence

Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence

Authors: Myron S. Cohen, M.D. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has generated a worldwide pandemic. The interruption of its spread depends on a combination of pharmacologic and nonpharmacologic interventions. Initial SARS-CoV-2 prevention includes social distancing, the use of face masks, environmental hygiene, and hand washing.1 Although […]

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Authors: Philippe Gautret 1, Jean-Christophe Lagier 2, Philippe Parola 1, Van Thuan Hoang 3, Line Meddeb 4, Morgane Mailhe 4, Barbara Doudier 4, Johan Courjon 5, Valérie Giordanengo 6, Vera Esteves Vieira 4, Hervé Tissot Dupont 2, Stéphane Honoré 7, Philippe Colson 2, Eric Chabrière 2, Bernard La Scola 2, Jean-Marc Rolain 2, Philippe Brouqui 2, Didier Raoult 8 Abstract Background: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads. […]

“Herd Immunity Is Not A Possibility”: Dr. Malone Vindicated After Oxford Prof Warns Over New Variants

Posted on | Posted on John Murphy | Leave a Comment on “Herd Immunity Is Not A Possibility”: Dr. Malone Vindicated After Oxford Prof Warns Over New Variants

Authors: Dr. Malone, TYLER DURDEN In one of the most appalling examples of Big Tech silencing scientists who refuse to withhold their criticisms of the mRNA technology behind the Moderna and Pfizer-BioNTech COVID vaccines, Dr. Robert Malone, a pioneer who helped develop mRNA vaccine technology, saw the credit for his contribution to medicine effectively erased from the […]

Posted on | Posted on John Murphy | Leave a Comment on

Contributors BC, CW, and YeW had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. CW and BC decided to publish the paper. BC, CW, YeW, PWH, TJ, and FGH provided input on the trial design. BC, CW, […]

Study: Remdesivir Does Not Reduce COVID Mortality

Posted on | Posted on John Murphy | Leave a Comment on Study: Remdesivir Does Not Reduce COVID Mortality

Authors: By Ralph Ellis October 19, 2020 — A large study sponsored by the World Health Organization found that remdesivir doesn’t help hospitalized patients with COVID-19 survive and doesn’t even shorten the recovery time of those who do survive. These findings contradict smaller studies which found remdesivir, an antiviral drug, helped hospitalized coronavirus patients recover […]

NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19

Posted on | Posted on John Murphy | Leave a Comment on NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19

Authors: NIAID Office of Communications Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by […]

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

Posted on | Posted on John Murphy | Leave a Comment on The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

Authors: By Jon Cohen, Kai KupferschmidtOct. 28, 2020 , 7:05 PM October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19—a deal potentially worth more than $1 […]

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

Posted on | Posted on John Murphy | Leave a Comment on Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

Authors:  Beigel, et al. Remdesivir for the Treatment of COVID-19 – A Preliminary Report. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2007764 (2020).   What The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in the New England Journal of Medicine. The preliminary analysis is based […]

Remdesivir for the Treatment of Covid-19 — Final Report

Posted on | Posted on John Murphy | Leave a Comment on Remdesivir for the Treatment of Covid-19 — Final Report

Authors: John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan Kline, M.D., M.P.H., Diego Lopez de Castilla, M.D., M.P.H., Robert W. Finberg, M.D., et al., for the ACTT-1 Study Group Members* Abstract BACKGROUND Although several therapeutic agents have been […]